Patent 10065958 was granted and assigned to Gilead Sciences on September, 2018 by the United States Patent and Trademark Office.
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: